International Stem Cell Corp. (ISCO) Slated to Discuss Q1 Earnings – Revenues Up 28%
International Stem Cell Corp., a California-based biotechnology company developing novel stem cell based therapies and biomedical products today provided a business update and announced financial results and for Q1 2014. "Obtaining clarity from the FDA on our Parkinson's disease program allows us to substantially lower the risk of unforeseen regulatory issues which could delay the program. By building the FDA's feedback into our plans, we will be able to prepare a stronger IND submission with an increased chance of a positive review," said Dr. Andrey Semechkin, the Company's CEO and Co-Chairman. "On the commercial side, on a year over year…